Finance
Molecular Partners to cut workforce by a quarter
Published by Global Banking & Finance Review®
Posted on June 10, 2025
1 min readLast updated: January 23, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on June 10, 2025
1 min readLast updated: January 23, 2026
Molecular Partners plans to reduce its workforce by 24% to boost efficiency and focus on key clinical assets, extending its cash runway into 2028.
ZURICH (Reuters) -Swiss biotech firm Molecular Partners said on Tuesday that it plans to reduce its workforce by up to 40 positions, or around 24%, as part of a strategic review to boost operational efficiency and focus on key clinical assets.
The company, which develops DARPin protein therapeutics - a new type of engineered protein drugs - said the cuts aim to extend its cash runway into 2028, beyond earlier guidance of 2027.
CEO Patrick Amstutz said the move will support the advancement of pipeline candidates MP0533 and MP0712, with clinical data expected in the second half of 2025.
(Reporting by John Revill, Editing by Miranda Murray)
Molecular Partners plans to reduce its workforce by around 24%, which translates to up to 40 positions.
The cuts are part of a strategic review aimed at extending the company's cash runway into 2028.
The workforce reduction will support the advancement of pipeline candidates MP0533 and MP0712.
Clinical data for the pipeline candidates MP0533 and MP0712 is expected in the second half of 2025.
Explore more articles in the Finance category
